Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Nobelpharma Launches Pediatric Sleep Aid Melatonin in China
January 19, 2026
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
- Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
- Rakuten Joins Hands with LOTTE Biologics to Boost Production for Photoimmunotherapy
January 15, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Cheplapharm to Take Over Japan MA for UCB’s Myocalm
January 15, 2026
- Meiji-Daito Generic Consortium Expands to Eight Members
January 15, 2026
- Daiichi Launches PIII Datroway Trial in TROP2 Positive NSCLC
January 15, 2026
- Opdivo-Yervoy Combo Expands Label for Colorectal Cancer in Taiwan: Ono
January 15, 2026
- UK Fund AVI Raises Stake in Wakamoto Above 10%
January 14, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…